nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C8—Paclitaxel—ovarian cancer	0.0413	0.19	CbGbCtD
Irbesartan—CYP2D6—Vinorelbine—ovarian cancer	0.0375	0.172	CbGbCtD
Irbesartan—CYP3A4—Topotecan—ovarian cancer	0.0338	0.156	CbGbCtD
Irbesartan—CYP2C9—Paclitaxel—ovarian cancer	0.0288	0.133	CbGbCtD
Irbesartan—CYP3A4—Vinorelbine—ovarian cancer	0.0238	0.11	CbGbCtD
Irbesartan—CYP3A4—Paclitaxel—ovarian cancer	0.0167	0.0771	CbGbCtD
Irbesartan—JUN—oviduct—ovarian cancer	0.0162	0.115	CbGeAlD
Irbesartan—CYP2D6—Doxorubicin—ovarian cancer	0.0142	0.0653	CbGbCtD
Irbesartan—CYP3A4—Docetaxel—ovarian cancer	0.0121	0.0557	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—ovarian cancer	0.00902	0.0415	CbGbCtD
Irbesartan—EDNRA—myometrium—ovarian cancer	0.00566	0.0403	CbGeAlD
Irbesartan—PTGS1—oviduct—ovarian cancer	0.00535	0.0381	CbGeAlD
Irbesartan—JUN—myometrium—ovarian cancer	0.00517	0.0368	CbGeAlD
Irbesartan—JUN—embryo—ovarian cancer	0.00497	0.0354	CbGeAlD
Irbesartan—EDNRA—uterine cervix—ovarian cancer	0.00441	0.0314	CbGeAlD
Irbesartan—EDNRA—decidua—ovarian cancer	0.0042	0.0299	CbGeAlD
Irbesartan—JUN—epithelium—ovarian cancer	0.00406	0.0289	CbGeAlD
Irbesartan—JUN—uterine cervix—ovarian cancer	0.00402	0.0286	CbGeAlD
Irbesartan—EDNRA—endometrium—ovarian cancer	0.00399	0.0284	CbGeAlD
Irbesartan—AGTR1—myometrium—ovarian cancer	0.00389	0.0277	CbGeAlD
Irbesartan—JUN—decidua—ovarian cancer	0.00383	0.0273	CbGeAlD
Irbesartan—EDNRA—uterus—ovarian cancer	0.00367	0.0262	CbGeAlD
Irbesartan—JUN—endometrium—ovarian cancer	0.00364	0.0259	CbGeAlD
Irbesartan—JUN—gonad—ovarian cancer	0.00337	0.024	CbGeAlD
Irbesartan—JUN—uterus—ovarian cancer	0.00335	0.0239	CbGeAlD
Irbesartan—AGTR1—epithelium—ovarian cancer	0.00305	0.0217	CbGeAlD
Irbesartan—AGTR1—uterine cervix—ovarian cancer	0.00303	0.0216	CbGeAlD
Irbesartan—JUN—female reproductive system—ovarian cancer	0.00301	0.0215	CbGeAlD
Irbesartan—EDNRA—female gonad—ovarian cancer	0.00301	0.0214	CbGeAlD
Irbesartan—EDNRA—vagina—ovarian cancer	0.00299	0.0213	CbGeAlD
Irbesartan—AGTR1—decidua—ovarian cancer	0.00289	0.0205	CbGeAlD
Irbesartan—JUN—bone marrow—ovarian cancer	0.00284	0.0203	CbGeAlD
Irbesartan—JUN—female gonad—ovarian cancer	0.00274	0.0195	CbGeAlD
Irbesartan—JUN—vagina—ovarian cancer	0.00273	0.0194	CbGeAlD
Irbesartan—EDNRA—testis—ovarian cancer	0.00267	0.019	CbGeAlD
Irbesartan—JUN—testis—ovarian cancer	0.00243	0.0173	CbGeAlD
Irbesartan—AGTR1—female reproductive system—ovarian cancer	0.00227	0.0162	CbGeAlD
Irbesartan—AGTR1—vagina—ovarian cancer	0.00205	0.0146	CbGeAlD
Irbesartan—EDNRA—lymph node—ovarian cancer	0.00193	0.0138	CbGeAlD
Irbesartan—AGTR1—testis—ovarian cancer	0.00183	0.013	CbGeAlD
Irbesartan—JUN—lymph node—ovarian cancer	0.00176	0.0126	CbGeAlD
Irbesartan—CYP2C8—endometrium—ovarian cancer	0.00149	0.0106	CbGeAlD
Irbesartan—PTGS1—epithelium—ovarian cancer	0.00134	0.00956	CbGeAlD
Irbesartan—PTGS1—uterine cervix—ovarian cancer	0.00133	0.00948	CbGeAlD
Irbesartan—AGTR1—lymph node—ovarian cancer	0.00133	0.00945	CbGeAlD
Irbesartan—CYP2C8—female reproductive system—ovarian cancer	0.00123	0.00876	CbGeAlD
Irbesartan—PTGS1—endometrium—ovarian cancer	0.0012	0.00857	CbGeAlD
Irbesartan—CYP2C8—vagina—ovarian cancer	0.00111	0.00792	CbGeAlD
Irbesartan—PTGS1—uterus—ovarian cancer	0.00111	0.0079	CbGeAlD
Irbesartan—CYP2C9—female reproductive system—ovarian cancer	0.00109	0.00778	CbGeAlD
Irbesartan—PTGS1—female reproductive system—ovarian cancer	0.000998	0.0071	CbGeAlD
Irbesartan—CYP2C8—testis—ovarian cancer	0.000993	0.00707	CbGeAlD
Irbesartan—PTGS1—female gonad—ovarian cancer	0.000908	0.00646	CbGeAlD
Irbesartan—PTGS1—vagina—ovarian cancer	0.000902	0.00642	CbGeAlD
Irbesartan—CYP3A4—female reproductive system—ovarian cancer	0.000833	0.00593	CbGeAlD
Irbesartan—CYP2D6—female reproductive system—ovarian cancer	0.00082	0.00584	CbGeAlD
Irbesartan—PTGS1—testis—ovarian cancer	0.000805	0.00573	CbGeAlD
Irbesartan—CYP2D6—female gonad—ovarian cancer	0.000746	0.00531	CbGeAlD
Irbesartan—CYP2D6—testis—ovarian cancer	0.000662	0.00471	CbGeAlD
Irbesartan—PTGS1—lymph node—ovarian cancer	0.000584	0.00416	CbGeAlD
Irbesartan—Loss of consciousness—Docetaxel—ovarian cancer	0.000262	0.000768	CcSEcCtD
Irbesartan—Pancreatitis—Doxorubicin—ovarian cancer	0.000261	0.000767	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000261	0.000766	CcSEcCtD
Irbesartan—Hyperglycaemia—Epirubicin—ovarian cancer	0.00026	0.000763	CcSEcCtD
Irbesartan—Cough—Docetaxel—ovarian cancer	0.00026	0.000762	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—ovarian cancer	0.00026	0.000762	CcSEcCtD
Irbesartan—Pneumonia—Epirubicin—ovarian cancer	0.000258	0.000758	CcSEcCtD
Irbesartan—Paraesthesia—Paclitaxel—ovarian cancer	0.000257	0.000755	CcSEcCtD
Irbesartan—Hypertension—Docetaxel—ovarian cancer	0.000257	0.000754	CcSEcCtD
Irbesartan—Dyspnoea—Paclitaxel—ovarian cancer	0.000255	0.00075	CcSEcCtD
Irbesartan—Somnolence—Paclitaxel—ovarian cancer	0.000255	0.000748	CcSEcCtD
Irbesartan—Chest pain—Docetaxel—ovarian cancer	0.000253	0.000743	CcSEcCtD
Irbesartan—Arthralgia—Docetaxel—ovarian cancer	0.000253	0.000743	CcSEcCtD
Irbesartan—Myalgia—Docetaxel—ovarian cancer	0.000253	0.000743	CcSEcCtD
Irbesartan—Nausea—Vinorelbine—ovarian cancer	0.000253	0.000743	CcSEcCtD
Irbesartan—Renal failure—Epirubicin—ovarian cancer	0.000252	0.000741	CcSEcCtD
Irbesartan—Dyspepsia—Paclitaxel—ovarian cancer	0.000252	0.00074	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000252	0.000738	CcSEcCtD
Irbesartan—Jaundice—Epirubicin—ovarian cancer	0.00025	0.000735	CcSEcCtD
Irbesartan—Urinary tract infection—Epirubicin—ovarian cancer	0.00025	0.000733	CcSEcCtD
Irbesartan—Conjunctivitis—Epirubicin—ovarian cancer	0.00025	0.000733	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—ovarian cancer	0.000249	0.000731	CcSEcCtD
Irbesartan—Decreased appetite—Paclitaxel—ovarian cancer	0.000249	0.000731	CcSEcCtD
Irbesartan—Dry mouth—Docetaxel—ovarian cancer	0.000248	0.000727	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000248	0.000727	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000247	0.000726	CcSEcCtD
Irbesartan—Fatigue—Paclitaxel—ovarian cancer	0.000247	0.000725	CcSEcCtD
Irbesartan—Constipation—Paclitaxel—ovarian cancer	0.000245	0.000719	CcSEcCtD
Irbesartan—Pain—Paclitaxel—ovarian cancer	0.000245	0.000719	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000243	0.000714	CcSEcCtD
Irbesartan—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000243	0.000713	CcSEcCtD
Irbesartan—Oedema—Docetaxel—ovarian cancer	0.000243	0.000713	CcSEcCtD
Irbesartan—Anaphylactic shock—Docetaxel—ovarian cancer	0.000243	0.000713	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—ovarian cancer	0.000243	0.000712	CcSEcCtD
Irbesartan—Epistaxis—Epirubicin—ovarian cancer	0.000242	0.000711	CcSEcCtD
Irbesartan—Infection—Docetaxel—ovarian cancer	0.000241	0.000708	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—ovarian cancer	0.00024	0.000706	CcSEcCtD
Irbesartan—Agranulocytosis—Epirubicin—ovarian cancer	0.00024	0.000703	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—ovarian cancer	0.000239	0.000701	CcSEcCtD
Irbesartan—Shock—Docetaxel—ovarian cancer	0.000239	0.000701	CcSEcCtD
Irbesartan—Nervous system disorder—Docetaxel—ovarian cancer	0.000238	0.000699	CcSEcCtD
Irbesartan—Thrombocytopenia—Docetaxel—ovarian cancer	0.000238	0.000698	CcSEcCtD
Irbesartan—Tachycardia—Docetaxel—ovarian cancer	0.000237	0.000696	CcSEcCtD
Irbesartan—Feeling abnormal—Paclitaxel—ovarian cancer	0.000236	0.000693	CcSEcCtD
Irbesartan—Skin disorder—Docetaxel—ovarian cancer	0.000236	0.000692	CcSEcCtD
Irbesartan—Bradycardia—Epirubicin—ovarian cancer	0.000235	0.000689	CcSEcCtD
Irbesartan—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000234	0.000688	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—ovarian cancer	0.000234	0.000686	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—ovarian cancer	0.000232	0.00068	CcSEcCtD
Irbesartan—Anorexia—Docetaxel—ovarian cancer	0.000231	0.000679	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—ovarian cancer	0.000231	0.000678	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—ovarian cancer	0.000231	0.000678	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—ovarian cancer	0.000231	0.000678	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—ovarian cancer	0.000231	0.000677	CcSEcCtD
Irbesartan—Hypoaesthesia—Epirubicin—ovarian cancer	0.000229	0.000673	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—ovarian cancer	0.000229	0.000672	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—ovarian cancer	0.000228	0.000668	CcSEcCtD
Irbesartan—Urticaria—Paclitaxel—ovarian cancer	0.000228	0.000668	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—ovarian cancer	0.000227	0.000667	CcSEcCtD
Irbesartan—Hypotension—Docetaxel—ovarian cancer	0.000227	0.000666	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—ovarian cancer	0.000227	0.000665	CcSEcCtD
Irbesartan—Abdominal pain—Paclitaxel—ovarian cancer	0.000226	0.000665	CcSEcCtD
Irbesartan—Body temperature increased—Paclitaxel—ovarian cancer	0.000226	0.000665	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—ovarian cancer	0.000226	0.000663	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000225	0.00066	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—ovarian cancer	0.000224	0.000658	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—ovarian cancer	0.000222	0.000652	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—ovarian cancer	0.000222	0.000651	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000221	0.000649	CcSEcCtD
Irbesartan—Paraesthesia—Docetaxel—ovarian cancer	0.000218	0.00064	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—ovarian cancer	0.000217	0.000637	CcSEcCtD
Irbesartan—Dyspnoea—Docetaxel—ovarian cancer	0.000216	0.000635	CcSEcCtD
Irbesartan—Somnolence—Docetaxel—ovarian cancer	0.000216	0.000634	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—ovarian cancer	0.000215	0.000631	CcSEcCtD
Irbesartan—Flushing—Epirubicin—ovarian cancer	0.000214	0.000628	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—ovarian cancer	0.000214	0.000628	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—ovarian cancer	0.000214	0.000628	CcSEcCtD
Irbesartan—Dyspepsia—Docetaxel—ovarian cancer	0.000214	0.000627	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—ovarian cancer	0.000213	0.000626	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000212	0.000623	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—ovarian cancer	0.000212	0.000621	CcSEcCtD
Irbesartan—Decreased appetite—Docetaxel—ovarian cancer	0.000211	0.00062	CcSEcCtD
Irbesartan—Hypersensitivity—Paclitaxel—ovarian cancer	0.000211	0.00062	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000211	0.000618	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—ovarian cancer	0.00021	0.000617	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00021	0.000615	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00021	0.000615	CcSEcCtD
Irbesartan—Fatigue—Docetaxel—ovarian cancer	0.000209	0.000614	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—ovarian cancer	0.000209	0.000614	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—ovarian cancer	0.000209	0.000614	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—ovarian cancer	0.000208	0.000611	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—ovarian cancer	0.000208	0.00061	CcSEcCtD
Irbesartan—Pain—Docetaxel—ovarian cancer	0.000208	0.000609	CcSEcCtD
Irbesartan—Constipation—Docetaxel—ovarian cancer	0.000208	0.000609	CcSEcCtD
Irbesartan—Chills—Epirubicin—ovarian cancer	0.000207	0.000607	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—ovarian cancer	0.000206	0.000604	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—ovarian cancer	0.000206	0.000603	CcSEcCtD
Irbesartan—Asthenia—Paclitaxel—ovarian cancer	0.000206	0.000603	CcSEcCtD
Irbesartan—Pruritus—Paclitaxel—ovarian cancer	0.000203	0.000595	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—ovarian cancer	0.000201	0.000589	CcSEcCtD
Irbesartan—Erythema—Epirubicin—ovarian cancer	0.000201	0.000589	CcSEcCtD
Irbesartan—Feeling abnormal—Docetaxel—ovarian cancer	0.0002	0.000587	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—ovarian cancer	0.000199	0.000584	CcSEcCtD
Irbesartan—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000199	0.000583	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—ovarian cancer	0.000198	0.000581	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—ovarian cancer	0.000198	0.000581	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—ovarian cancer	0.000198	0.00058	CcSEcCtD
Irbesartan—Tension—Epirubicin—ovarian cancer	0.000197	0.000578	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—ovarian cancer	0.000197	0.000577	CcSEcCtD
Irbesartan—Diarrhoea—Paclitaxel—ovarian cancer	0.000196	0.000575	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—ovarian cancer	0.000195	0.000572	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—ovarian cancer	0.000194	0.000568	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—ovarian cancer	0.000193	0.000566	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—ovarian cancer	0.000193	0.000566	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000192	0.000564	CcSEcCtD
Irbesartan—Abdominal pain—Docetaxel—ovarian cancer	0.000192	0.000563	CcSEcCtD
Irbesartan—Body temperature increased—Docetaxel—ovarian cancer	0.000192	0.000563	CcSEcCtD
Irbesartan—Chills—Doxorubicin—ovarian cancer	0.000191	0.000562	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—ovarian cancer	0.000191	0.000559	CcSEcCtD
Irbesartan—Dizziness—Paclitaxel—ovarian cancer	0.000189	0.000556	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—ovarian cancer	0.000189	0.000555	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—ovarian cancer	0.000186	0.000547	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—ovarian cancer	0.000186	0.000545	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—ovarian cancer	0.000186	0.000545	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—ovarian cancer	0.000185	0.000544	CcSEcCtD
Irbesartan—Agitation—Epirubicin—ovarian cancer	0.000184	0.000541	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—ovarian cancer	0.000183	0.000537	CcSEcCtD
Irbesartan—Tension—Doxorubicin—ovarian cancer	0.000182	0.000535	CcSEcCtD
Irbesartan—Vomiting—Paclitaxel—ovarian cancer	0.000182	0.000535	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—ovarian cancer	0.000182	0.000534	CcSEcCtD
Irbesartan—Malaise—Epirubicin—ovarian cancer	0.000181	0.000531	CcSEcCtD
Irbesartan—Rash—Paclitaxel—ovarian cancer	0.000181	0.00053	CcSEcCtD
Irbesartan—Dermatitis—Paclitaxel—ovarian cancer	0.00018	0.00053	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—ovarian cancer	0.00018	0.000529	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—ovarian cancer	0.00018	0.000529	CcSEcCtD
Irbesartan—Syncope—Epirubicin—ovarian cancer	0.00018	0.000528	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—ovarian cancer	0.00018	0.000527	CcSEcCtD
Irbesartan—Headache—Paclitaxel—ovarian cancer	0.000179	0.000527	CcSEcCtD
Irbesartan—Hypersensitivity—Docetaxel—ovarian cancer	0.000179	0.000525	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—ovarian cancer	0.000179	0.000524	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—ovarian cancer	0.000176	0.000518	CcSEcCtD
Irbesartan—Cough—Epirubicin—ovarian cancer	0.000175	0.000514	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—ovarian cancer	0.000175	0.000514	CcSEcCtD
Irbesartan—Asthenia—Docetaxel—ovarian cancer	0.000174	0.000511	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—ovarian cancer	0.000173	0.000509	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000172	0.000506	CcSEcCtD
Irbesartan—Pruritus—Docetaxel—ovarian cancer	0.000172	0.000504	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—ovarian cancer	0.000172	0.000504	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—ovarian cancer	0.000171	0.000501	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—ovarian cancer	0.000171	0.000501	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—ovarian cancer	0.000171	0.000501	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—ovarian cancer	0.000171	0.000501	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—ovarian cancer	0.00017	0.0005	CcSEcCtD
Irbesartan—Nausea—Paclitaxel—ovarian cancer	0.00017	0.000499	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00017	0.000498	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—ovarian cancer	0.000169	0.000495	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—ovarian cancer	0.000167	0.000491	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—ovarian cancer	0.000167	0.00049	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—ovarian cancer	0.000167	0.00049	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—ovarian cancer	0.000167	0.000489	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—ovarian cancer	0.000166	0.000488	CcSEcCtD
Irbesartan—Diarrhoea—Docetaxel—ovarian cancer	0.000166	0.000488	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—ovarian cancer	0.000164	0.000481	CcSEcCtD
Irbesartan—Oedema—Epirubicin—ovarian cancer	0.000164	0.000481	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—ovarian cancer	0.000163	0.000479	CcSEcCtD
Irbesartan—Infection—Epirubicin—ovarian cancer	0.000163	0.000478	CcSEcCtD
Irbesartan—Cough—Doxorubicin—ovarian cancer	0.000162	0.000476	CcSEcCtD
Irbesartan—Shock—Epirubicin—ovarian cancer	0.000161	0.000473	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—ovarian cancer	0.000161	0.000471	CcSEcCtD
Irbesartan—Dizziness—Docetaxel—ovarian cancer	0.000161	0.000471	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—ovarian cancer	0.00016	0.000471	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—ovarian cancer	0.00016	0.000471	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—ovarian cancer	0.00016	0.000469	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—ovarian cancer	0.000159	0.000467	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—ovarian cancer	0.000158	0.000465	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—ovarian cancer	0.000158	0.000464	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—ovarian cancer	0.000158	0.000464	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—ovarian cancer	0.000158	0.000464	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—ovarian cancer	0.000158	0.000462	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000157	0.000461	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—ovarian cancer	0.000156	0.000458	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—ovarian cancer	0.000156	0.000458	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—ovarian cancer	0.000155	0.000454	CcSEcCtD
Irbesartan—Vomiting—Docetaxel—ovarian cancer	0.000154	0.000453	CcSEcCtD
Irbesartan—Rash—Docetaxel—ovarian cancer	0.000153	0.000449	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—ovarian cancer	0.000153	0.000449	CcSEcCtD
Irbesartan—Dermatitis—Docetaxel—ovarian cancer	0.000153	0.000449	CcSEcCtD
Irbesartan—Headache—Docetaxel—ovarian cancer	0.000152	0.000447	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000152	0.000445	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—ovarian cancer	0.000152	0.000445	CcSEcCtD
Irbesartan—Infection—Doxorubicin—ovarian cancer	0.000151	0.000442	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000149	0.000438	CcSEcCtD
Irbesartan—Shock—Doxorubicin—ovarian cancer	0.000149	0.000438	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—ovarian cancer	0.000149	0.000436	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000148	0.000436	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—ovarian cancer	0.000148	0.000434	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—ovarian cancer	0.000147	0.000432	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—ovarian cancer	0.000147	0.000432	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000147	0.00043	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—ovarian cancer	0.000146	0.000429	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—ovarian cancer	0.000146	0.000427	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—ovarian cancer	0.000144	0.000424	CcSEcCtD
Irbesartan—Nausea—Docetaxel—ovarian cancer	0.000144	0.000423	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—ovarian cancer	0.000144	0.000423	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—ovarian cancer	0.000142	0.000418	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—ovarian cancer	0.000142	0.000416	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000141	0.000415	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—ovarian cancer	0.000141	0.000414	CcSEcCtD
Irbesartan—Constipation—Epirubicin—ovarian cancer	0.00014	0.000411	CcSEcCtD
Irbesartan—Pain—Epirubicin—ovarian cancer	0.00014	0.000411	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000138	0.000405	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—ovarian cancer	0.000136	0.000399	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—ovarian cancer	0.000135	0.000397	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—ovarian cancer	0.000135	0.000396	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—ovarian cancer	0.000135	0.000395	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000134	0.000393	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—ovarian cancer	0.000133	0.000392	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—ovarian cancer	0.000132	0.000387	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000131	0.000384	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—ovarian cancer	0.000131	0.000383	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—ovarian cancer	0.00013	0.000382	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—ovarian cancer	0.00013	0.00038	CcSEcCtD
Irbesartan—Pain—Doxorubicin—ovarian cancer	0.00013	0.00038	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—ovarian cancer	0.000129	0.00038	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—ovarian cancer	0.000129	0.00038	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—ovarian cancer	0.000125	0.000367	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000124	0.000364	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—ovarian cancer	0.000121	0.000354	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—ovarian cancer	0.00012	0.000353	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—ovarian cancer	0.00012	0.000352	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—ovarian cancer	0.00012	0.000352	CcSEcCtD
Irbesartan—Asthenia—Epirubicin—ovarian cancer	0.000118	0.000345	CcSEcCtD
Irbesartan—Pruritus—Epirubicin—ovarian cancer	0.000116	0.00034	CcSEcCtD
Irbesartan—Diarrhoea—Epirubicin—ovarian cancer	0.000112	0.000329	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—ovarian cancer	0.000112	0.000328	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—ovarian cancer	0.000109	0.000319	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—ovarian cancer	0.000108	0.000318	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—ovarian cancer	0.000107	0.000315	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—ovarian cancer	0.000104	0.000306	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—ovarian cancer	0.000104	0.000304	CcSEcCtD
Irbesartan—Rash—Epirubicin—ovarian cancer	0.000103	0.000303	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—ovarian cancer	0.000103	0.000303	CcSEcCtD
Irbesartan—Headache—Epirubicin—ovarian cancer	0.000103	0.000301	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—ovarian cancer	0.0001	0.000294	CcSEcCtD
Irbesartan—Nausea—Epirubicin—ovarian cancer	9.73e-05	0.000286	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—ovarian cancer	9.64e-05	0.000283	CcSEcCtD
Irbesartan—Rash—Doxorubicin—ovarian cancer	9.56e-05	0.00028	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—ovarian cancer	9.55e-05	0.00028	CcSEcCtD
Irbesartan—Headache—Doxorubicin—ovarian cancer	9.49e-05	0.000279	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—ovarian cancer	9e-05	0.000264	CcSEcCtD
Irbesartan—CYP2C9—Metabolism—BRIP1—ovarian cancer	3.37e-05	0.000112	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CG—ovarian cancer	3.36e-05	0.000111	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CAV1—ovarian cancer	3.33e-05	0.000111	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—ovarian cancer	3.33e-05	0.00011	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SLC2A1—ovarian cancer	3.33e-05	0.00011	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYTB—ovarian cancer	3.29e-05	0.000109	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.26e-05	0.000108	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MAPK1—ovarian cancer	3.24e-05	0.000108	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—ovarian cancer	3.24e-05	0.000108	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDH1—ovarian cancer	3.23e-05	0.000107	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.22e-05	0.000107	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ESR1—ovarian cancer	3.21e-05	0.000107	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP1B1—ovarian cancer	3.19e-05	0.000106	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6ST—ovarian cancer	3.16e-05	0.000105	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CD—ovarian cancer	3.09e-05	0.000102	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—ovarian cancer	3.06e-05	0.000102	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PIK3CA—ovarian cancer	3.06e-05	0.000101	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CG—ovarian cancer	3.04e-05	0.000101	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—APC—ovarian cancer	3.04e-05	0.000101	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—ovarian cancer	3.04e-05	0.000101	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.02e-05	0.0001	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB2—ovarian cancer	3.01e-05	9.96e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MTOR—ovarian cancer	2.97e-05	9.83e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CB—ovarian cancer	2.97e-05	9.83e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CD—ovarian cancer	2.96e-05	9.8e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—MAPK3—ovarian cancer	2.91e-05	9.64e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPP1CC—ovarian cancer	2.88e-05	9.54e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—BRIP1—ovarian cancer	2.88e-05	9.54e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL8—ovarian cancer	2.85e-05	9.45e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—ovarian cancer	2.83e-05	9.39e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPP2R1A—ovarian cancer	2.83e-05	9.38e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.82e-05	9.34e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PIK3CA—ovarian cancer	2.82e-05	9.33e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDKN1B—ovarian cancer	2.78e-05	9.23e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—YAP1—ovarian cancer	2.78e-05	9.2e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—MAPK1—ovarian cancer	2.77e-05	9.17e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—ovarian cancer	2.77e-05	9.17e-05	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—ovarian cancer	2.75e-05	9.13e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.75e-05	9.11e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CASP3—ovarian cancer	2.73e-05	9.04e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB2—ovarian cancer	2.73e-05	9.03e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—ovarian cancer	2.72e-05	9.03e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL6—ovarian cancer	2.71e-05	8.98e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TERT—ovarian cancer	2.69e-05	8.93e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CB—ovarian cancer	2.69e-05	8.91e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MTOR—ovarian cancer	2.69e-05	8.91e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CD—ovarian cancer	2.67e-05	8.85e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—ovarian cancer	2.66e-05	8.8e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—ovarian cancer	2.65e-05	8.77e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CTNNB1—ovarian cancer	2.63e-05	8.72e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ABCB1—ovarian cancer	2.63e-05	8.71e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—ovarian cancer	2.61e-05	8.67e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—ovarian cancer	2.6e-05	8.63e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TYMS—ovarian cancer	2.58e-05	8.56e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—ovarian cancer	2.58e-05	8.55e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CB—ovarian cancer	2.58e-05	8.54e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTEN—ovarian cancer	2.56e-05	8.5e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYTB—ovarian cancer	2.54e-05	8.43e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1B—ovarian cancer	2.52e-05	8.37e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—ovarian cancer	2.5e-05	8.29e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—ovarian cancer	2.49e-05	8.26e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CAV1—ovarian cancer	2.49e-05	8.26e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—ovarian cancer	2.47e-05	8.19e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.46e-05	8.14e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.42e-05	8.01e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—ovarian cancer	2.4e-05	7.96e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ESR1—ovarian cancer	2.4e-05	7.96e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—ovarian cancer	2.38e-05	7.9e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6ST—ovarian cancer	2.36e-05	7.83e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—ovarian cancer	2.36e-05	7.82e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CB—ovarian cancer	2.33e-05	7.71e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MTOR—ovarian cancer	2.33e-05	7.71e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—ovarian cancer	2.32e-05	7.7e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—ovarian cancer	2.32e-05	7.67e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—ovarian cancer	2.3e-05	7.62e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—ovarian cancer	2.29e-05	7.6e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—ovarian cancer	2.29e-05	7.58e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—YAP1—ovarian cancer	2.28e-05	7.56e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APC—ovarian cancer	2.27e-05	7.52e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CG—ovarian cancer	2.27e-05	7.52e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—FASN—ovarian cancer	2.26e-05	7.5e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—YAP1—ovarian cancer	2.26e-05	7.49e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—ovarian cancer	2.24e-05	7.41e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.24e-05	7.41e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—ovarian cancer	2.23e-05	7.38e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC5A5—ovarian cancer	2.23e-05	7.38e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—ovarian cancer	2.22e-05	7.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.22e-05	7.36e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.22e-05	7.36e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK3—ovarian cancer	2.19e-05	7.26e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1B—ovarian cancer	2.18e-05	7.24e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—ovarian cancer	2.16e-05	7.16e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC2A1—ovarian cancer	2.15e-05	7.13e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—ovarian cancer	2.14e-05	7.1e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—ovarian cancer	2.14e-05	7.08e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—ovarian cancer	2.13e-05	7.06e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—ovarian cancer	2.13e-05	7.05e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.11e-05	6.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.1e-05	6.95e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—ovarian cancer	2.08e-05	6.91e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK1—ovarian cancer	2.08e-05	6.91e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—ovarian cancer	2.08e-05	6.91e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CAV1—ovarian cancer	2.08e-05	6.89e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—ovarian cancer	2.08e-05	6.89e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—ovarian cancer	2.07e-05	6.87e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—ovarian cancer	2.06e-05	6.84e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1B1—ovarian cancer	2.06e-05	6.83e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—ovarian cancer	2.02e-05	6.71e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—ovarian cancer	2.01e-05	6.67e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CD—ovarian cancer	2e-05	6.61e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.99e-05	6.59e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK3—ovarian cancer	1.99e-05	6.58e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—ovarian cancer	1.97e-05	6.52e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.97e-05	6.52e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—ovarian cancer	1.96e-05	6.5e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—YAP1—ovarian cancer	1.93e-05	6.4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.91e-05	6.33e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CG—ovarian cancer	1.89e-05	6.28e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK1—ovarian cancer	1.89e-05	6.26e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—ovarian cancer	1.89e-05	6.26e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—FASN—ovarian cancer	1.86e-05	6.16e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—FASN—ovarian cancer	1.84e-05	6.11e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	1.83e-05	6.06e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.83e-05	6.06e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.82e-05	6.03e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—ovarian cancer	1.82e-05	6.02e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.81e-05	6.01e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—ovarian cancer	1.81e-05	5.99e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—ovarian cancer	1.8e-05	5.96e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—ovarian cancer	1.79e-05	5.95e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—ovarian cancer	1.78e-05	5.92e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.77e-05	5.85e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—ovarian cancer	1.76e-05	5.84e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.75e-05	5.8e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—ovarian cancer	1.75e-05	5.8e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CB—ovarian cancer	1.74e-05	5.76e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MTOR—ovarian cancer	1.74e-05	5.76e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK3—ovarian cancer	1.72e-05	5.7e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.71e-05	5.68e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—ovarian cancer	1.7e-05	5.63e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.69e-05	5.61e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.68e-05	5.57e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.68e-05	5.56e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—ovarian cancer	1.67e-05	5.54e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—ovarian cancer	1.67e-05	5.54e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—ovarian cancer	1.67e-05	5.54e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMS—ovarian cancer	1.67e-05	5.53e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CD—ovarian cancer	1.67e-05	5.52e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—ovarian cancer	1.64e-05	5.43e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK1—ovarian cancer	1.64e-05	5.42e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—ovarian cancer	1.63e-05	5.42e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1B—ovarian cancer	1.63e-05	5.41e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—ovarian cancer	1.6e-05	5.31e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—ovarian cancer	1.6e-05	5.3e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—ovarian cancer	1.6e-05	5.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—FASN—ovarian cancer	1.57e-05	5.22e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—ovarian cancer	1.57e-05	5.21e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—ovarian cancer	1.56e-05	5.16e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.55e-05	5.13e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—ovarian cancer	1.54e-05	5.12e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—ovarian cancer	1.54e-05	5.11e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—ovarian cancer	1.52e-05	5.03e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—ovarian cancer	1.51e-05	5.01e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—ovarian cancer	1.5e-05	4.98e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.5e-05	4.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.5e-05	4.96e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—YAP1—ovarian cancer	1.49e-05	4.94e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.49e-05	4.93e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.48e-05	4.91e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—ovarian cancer	1.48e-05	4.9e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.46e-05	4.85e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—ovarian cancer	1.45e-05	4.81e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CB—ovarian cancer	1.45e-05	4.81e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.43e-05	4.75e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—ovarian cancer	1.42e-05	4.7e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.39e-05	4.62e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.38e-05	4.58e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—ovarian cancer	1.37e-05	4.55e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMS—ovarian cancer	1.37e-05	4.54e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—ovarian cancer	1.36e-05	4.5e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMS—ovarian cancer	1.36e-05	4.5e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—ovarian cancer	1.34e-05	4.45e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CAV1—ovarian cancer	1.34e-05	4.45e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—ovarian cancer	1.34e-05	4.44e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—ovarian cancer	1.34e-05	4.44e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—ovarian cancer	1.31e-05	4.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK3—ovarian cancer	1.28e-05	4.26e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.28e-05	4.25e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—ovarian cancer	1.28e-05	4.25e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.27e-05	4.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.27e-05	4.19e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—ovarian cancer	1.26e-05	4.16e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—ovarian cancer	1.25e-05	4.16e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—ovarian cancer	1.25e-05	4.14e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.22e-05	4.06e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK1—ovarian cancer	1.22e-05	4.05e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—ovarian cancer	1.22e-05	4.05e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—FASN—ovarian cancer	1.21e-05	4.03e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.2e-05	3.96e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.18e-05	3.91e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMS—ovarian cancer	1.16e-05	3.84e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—ovarian cancer	1.16e-05	3.84e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.15e-05	3.83e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—ovarian cancer	1.15e-05	3.82e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.11e-05	3.67e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CAV1—ovarian cancer	1.1e-05	3.66e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CAV1—ovarian cancer	1.09e-05	3.62e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.08e-05	3.57e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—ovarian cancer	1.06e-05	3.51e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.04e-05	3.46e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—ovarian cancer	1.03e-05	3.4e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1e-05	3.33e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—ovarian cancer	9.96e-06	3.3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	9.81e-06	3.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—ovarian cancer	9.81e-06	3.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—ovarian cancer	9.39e-06	3.11e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CB—ovarian cancer	9.38e-06	3.11e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CAV1—ovarian cancer	9.34e-06	3.1e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—ovarian cancer	9.11e-06	3.02e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMS—ovarian cancer	8.95e-06	2.97e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.93e-06	2.96e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—ovarian cancer	8.85e-06	2.93e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CD—ovarian cancer	8.83e-06	2.93e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CD—ovarian cancer	8.76e-06	2.9e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—ovarian cancer	8.66e-06	2.87e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—ovarian cancer	8.51e-06	2.82e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—ovarian cancer	8.1e-06	2.69e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CB—ovarian cancer	7.7e-06	2.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CB—ovarian cancer	7.63e-06	2.53e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CD—ovarian cancer	7.48e-06	2.48e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—ovarian cancer	7.23e-06	2.4e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CAV1—ovarian cancer	7.21e-06	2.39e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—ovarian cancer	6.65e-06	2.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—ovarian cancer	6.59e-06	2.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—ovarian cancer	6.57e-06	2.18e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CB—ovarian cancer	6.52e-06	2.16e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CD—ovarian cancer	5.77e-06	1.91e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—ovarian cancer	5.72e-06	1.89e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—ovarian cancer	5.64e-06	1.87e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CB—ovarian cancer	5.03e-06	1.67e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—ovarian cancer	4.69e-06	1.56e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—ovarian cancer	4.67e-06	1.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—ovarian cancer	4.65e-06	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—ovarian cancer	4.35e-06	1.44e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—ovarian cancer	3.98e-06	1.32e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—ovarian cancer	3.83e-06	1.27e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—ovarian cancer	3.8e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—ovarian cancer	3.25e-06	1.08e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.07e-06	1.02e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—ovarian cancer	2.51e-06	8.31e-06	CbGpPWpGaD
